65,437 trials
Osteoarthritis · Traumatic Arthritis · Avascular Necrosis of the Femoral Condyle
Primary: Group 2 - Total Knee Society Score (KSS) — 92.2; 78.5; 118.2; 96.7 score on a scale
Drug Resistant Partial Onset Seizure
Primary: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — -21.28; -10.25 Percent change — p=0.1788
Tobacco Cessation
Primary: Number of Participants With Self-reported 30-day Point Prevalence Abstinence (ITT) — 314; 239 Participants
HIV Infection
Primary: Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] — 4; 1; 19 Participants
Pain, Head · Pain Syndrome · Temporomandibular Disorder
Primary: Change in Jaw Pain as Reported by Patient on Visual Analog Scale (VAS) — 58; 54; -19; -14 score on a scale — p=0.80
Surgery
Primary: Opioid Consumption 12 Hours Post Operative — 19.4; 15.6 IV morphine mg equivalents
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Postoperative Kidney Injury
Primary: Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes] — 2.9; 4.0; 5.0; 4.7 ng/ml — p=0.15
Retinopathy of Prematurity (ROP)
Primary: Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms — 66.8; 64.6; 62.1 Score on a scale
Atopic Dermatitis
Primary: Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 — -6.03; -6.44; -4.84 score on a scale — p=0.356
Hookah Tobacco Smoking
Primary: Hookah Tobacco Initiation — 11; 5 Participants
Hepatocellular Carcinoma
Primary: Number of Participants With Local Tumor Response According to mRECIST — 26; 0; 0; 3 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants
Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis — 19.15; NA months — p=0.0007
HIV/AIDS · Substance Use Disorders
Primary: Number of Participants With Undetectable HIV Viral Load — 2; 3 Participants